Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1CNS 1

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Esthesioneuroblastoma, Olfactory 1Carcinoma, Medullary 1Adenocarcinoma, Follicular 1

Interventions

Paclitaxel 10trametinib 9dabrafenib 9pembrolizumab 5lenvatinib 5fosbretabulin 4Sorafenib 4Radiotherapy, Intensity-Modulated 4Doxorubicin 4Radiotherapy 3Cisplatin 3pazopanib 2efatutazone 2combretastatin 2cobimetinib 2cemiplimab 2atezolizumab 2aldesleukin 2Vemurafenib 2Trastuzumab 2Taxes 2Nivolumab 2Gefitinib 2Filgrastim 2Everolimus 2Docetaxel 2Carboplatin 2Bevacizumab 2zimberelimab 1vandetanib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Thyroid Carcinoma, Anaplastic × Semaxinib × Endocrine × Clear all
NCT00005647 2010-06-10

SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck

Case Comprehensive Cancer Center

Phase 1 Completed
12 enrolled
CNSEndocrineHead & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Salivary Gland Neoplasms, Thyroid Neoplasms, Adenocarcinoma, Follicular, Carcinoma, Medullary, Esthesioneuroblastoma, Olfactory, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡